New combo therapy aims to shield gut in transplant patients
NCT ID NCT06598332
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study was designed to test whether adding a drug called 5-azacytidine (AZA) to standard steroid treatment is safe and feasible for people with gut graft-versus-host disease (GVHD) after a stem cell transplant. GVHD occurs when donor cells attack the patient's body, and gut involvement can cause long-term damage. The trial planned to enroll patients aged 12 and older, but it was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE (GVHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.